GlassScriptPhysician profile
Deborah K Nunemaker
NPI 1801249859
$7,931.39
in general payments reported to CMS, 2019-2025
21 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,206 · 2022: $1,703 · 2023: $1,820 · 2024: $1,385 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,815 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,815.12 |
| Education | $207.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,426.86 | 2021-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,019.00 | 2021-2025 | Tremfya |
| Pfizer INC. | $860.84 | 2021-2025 | |
| Abbvie INC. | $743.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $529.82 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $514.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $415.47 | 2021-2025 | Saphnelo |
| Ucb, INC. | $258.26 | 2021-2024 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $211.23 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $174.08 | 2022-2025 | Tymlos |
| Cumberland Pharmaceuticals, INC. | $168.34 | 2022-2023 | Reditrex |
| Mallinckrodt Hospital Products INC. | $153.04 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $92.64 | 2024 | |
| Aurinia Pharma U.S., INC. | $80.20 | 2021-2023 | Lupkynis |
| Lilly USA, LLC | $76.09 | 2022-2024 | Taltz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $62.59 | 2023-2024 | Idacio |
| Actelion Pharmaceuticals US, INC. | $45.58 | 2021-2022 | |
| Organon LLC | $44.64 | 2025 | Renflexis, Hadlima |
| Genzyme Corporation | $26.65 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $14.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Nunemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.